News | July 02, 2022
Ardelyx gets into $20 million financing agreement with HealthCare Royalty Partners
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
First and only PARP inhibitor to improve invasive disease-free survival in patients
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
It´s the first trial to demonstrate the benefits of dual pathway inhibition
TRIPS waiver for five years agreed in the recently concluded WTO will help countries manufacture COVID vaccines to deal with the pandemic
Both manufacturing facilities are based out of Benguluru, India
Subscribe To Our Newsletter & Stay Updated
